Methylene Blue

Methylene blue is a bright blue synthetic dye that doubles as a medicine.

Methylene blue acts as a potent MAO inhibitor and is used to treat methemoglobinemia by converting methemoglobin back to hemoglobin. [Source: Peptide Dosing Protocols]

Methylene blue acts primarily as a potent MAO inhibitor, which can lead to increased levels of serotonin in the brain. This mechanism is particularly relevant when considering its interactions with serotonergic medications, as it can precipitate serotonin syndrome, a potentially life-threatening condition. The drug has been shown to have a hormetic effect, where low doses (approximately 0.5-4 mg/kg) can enhance cognitive function, while higher doses (around 10 mg/kg) may reverse these benefits. This duality in dosing highlights the importance of careful administration and monitoring.

In clinical settings, methylene blue is FDA-approved for the treatment of acquired methemoglobinemia, a blood disorder where hemoglobin is unable to effectively release oxygen to body tissues. The drug works by reducing methemoglobin back to hemoglobin, thereby restoring its oxygen-carrying capacity. This rapid action is crucial in emergency situations, with improvements in methemoglobin levels often observed within an hour of administration.

Research has also explored the cognitive effects of methylene blue, with small human trials indicating that a single low oral dose can increase brain activity related to attention and memory tasks. For instance, a 2017 study by Rodriguez et al. published in Radiology (N=26) found significant increases in brain activity following administration. Other studies have investigated its potential in mood disorders, linking its MAOI activity to mood enhancement, although these findings remain preliminary and not yet established as a treatment standard. Additionally, preclinical studies have suggested antimicrobial and antiviral properties, including activity against SARS-CoV-2, but these uses are not FDA-approved and remain unproven in human subjects. [Source: Peptide Dosing Protocols]

Provider notes: [PDP compound] methylene-blue